Peptide Comparison
MazdutidevsSurvodutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
At a Glance
Quick
comparison
Dose Range
Mazdutide
3 mg–9 mg mg
Survodutide
2.4 mg–6 mg mg
Frequency
Mazdutide
Once daily
Survodutide
Once daily
Administration
Mazdutide
Subcutaneous injection
Survodutide
subcutaneous injection
Cycle Length
Mazdutide
Ongoing/indefinite
Survodutide
Ongoing/indefinite
Onset Speed
Mazdutide
Moderate (1-2 weeks)
Survodutide
Moderate (1-2 weeks)
Evidence Level
Mazdutide
Strong human trials (Phase 3 or FDA approved)
Survodutide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Weight Loss
Blood Sugar Control
Metabolic Health
Weight Management
Technical Data
Compound
specifications
Mazdutide
Molecular Formula
C210H322N46O67
Molecular Weight
4563.1 Da
Half-Life
Approximately 8 days
Bioavailability
Subcutaneous bioavailability characteristic of acylated peptide analogs
CAS Number
2259884-03-0
Survodutide
Molecular Formula
C192H289N47O61
Molecular Weight
4,231.6 Da
Half-Life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
CAS Number
2805997-46-8
Applications
Best
suited for
Mazdutide
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide
Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Mazdutide
Common
- Nausea
- Diarrhea
- Decreased Appetite
Uncommon
- Vomiting
- Injection Site Reactions
Serious
- Acute Pancreatitis
- Acute Cholecystitis and Biliary Disease
- Severe Nausea and Gastrointestinal Intolerance
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Research Status
Safety
& evidence
Mazdutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Mazdutide (Roche/Carmot GLP-1/GCG/GIP triple agonist) completed Phase Ib with generally favorable safety profile but dose-limiting gastrointestinal side effects. Nausea/vomiting occur in 40-50% of subjects at higher doses; weight loss averaging 12-18% observed. Pancreatitis risk monitoring required; calcitonin elevation consistent with GCG activation. Heart rate increases 5-8 bpm; no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma or MEN2 syndrome
- xKnown hypersensitivity to mazdutide or any formulation excipients
- xHistory of severe pancreatitis
- xSevere renal impairment (eGFR <15 mL/min) without clinical data
Survodutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (nausea up to 75% at highest doses, diarrhea, vomiting) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xKnown hypersensitivity to survodutide or excipients
- xHistory of pancreatitis (caution advised with GLP-1 receptor agonists)
Decision Guide
Which is
right for you?
Choose Mazdutide if...
- Individuals seeking substantial weight loss exceeding 15% body weight
- Adults with type 2 diabetes requiring superior glycemic management
- Patients with obesity-related metabolic comorbidities
- Those seeking dual-mechanism metabolic therapy
Choose Survodutide if...
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement